3,4-Dihydro-2H-pyrido[3,2-b]-1,4-oxazine

Catalog No.: 
ACTKXY673
CAS No.: 
20348-23-6
Molecular Formula: 
C7H8N2O
Molecular Weight: 
136.15
3,4-Dihydro-2H-pyrido[3,2-b]-1,4-oxazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g97%$95.00In stockIn stock
25g97%$404.00In stockIn stock
100g97%$1568.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3,4-Dihydro-2H-pyrido[3,2-b]-1,4-oxazine
IUPAC Name3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine
MDL No.MFCD09025907
Molecular FormulaC7H8N2O
Molecular Weight136.15
SMILESC1COC2=CC=CN=C2N1
InChI KeyQQVXDMFULJVZLA-UHFFFAOYSA-N
Synonym20348-23-6 | 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine | 3,4-Dihydro-2H-pyrido[3,2-b]-1,4-oxazine | 2H-PYRIDO[3,2-B]-1,4-OXAZINE, 3,4-DIHYDRO- | 2H,3H,4H-pyrido[3,2-b][1,4]oxazine | MFCD09025907 | C7H8N2O | dihydropyrido[1,4]oxazine | 2H-Pyrido[3,2-b]-1,4-oxazine,3,4-dihy
CAS No.20348-23-6
PubChem CID13196538

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302+H312+H332-H315-H319-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACTKXY673 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACUAFO936 route compound structure diagram
    ACUAFO93620348-09-8In Stock
  2. Then
  3. ACTKXY673 route product structure diagram
    ACTKXY67320348-23-6In Stock
Inquiry

2. ACTKXY673 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACVNMY715 route compound structure diagram
    ACVNMY71516867-03-1In Stock
  2. Then
  3. ACTKXY673 route product structure diagram
    ACTKXY67320348-23-6In Stock
Inquiry

3. ACTKXY673 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTKXY673 route product structure diagram
    ACTKXY67320348-23-6In Stock
Inquiry

Comments (0)